So you took the test. You have a number — or more likely a small constellation: a log contrast sensitivity score at each spatial frequency, an AULCSF summary, a curve plotted against a normative band. What's in front of you is a piece of evidence about your own visual system that didn't exist before.
The question is what to do with it. This post is a guide to the answer most people don't get to in time: bring it to your next eye-care appointment. Not as a verdict, not as an argument, not as something your provider needs to validate — as one more data point on the table, used to make the conversation better than the one that would have happened without it.
Underneath is one assumption: your eye doctor is on your side, and they have less time than either of you would like. The job of the data is to make those minutes count for more.
Why bringing data is worth the effort
A comprehensive eye exam runs twenty to thirty minutes. Your provider works through refraction, slit-lamp, intraocular pressure, fundus exam, sometimes visual fields, often dilation. The Snellen chart shows up early, takes ninety seconds, and produces a tidy number — often 20/20.
Contrast sensitivity is rarely part of that flow. The Pelli-Robson chart has been the reference standard since 1988, but most general optometry offices don't keep one on the wall (Pelli, Robson & Wilkins, 1988). It's not a slight — the test isn't part of the standard battery, so it gets used when something specific prompts it.
Which means: if contrast sensitivity is what's bothering you — "my night driving has gotten harder," "faces feel flatter than they used to" — the most useful thing you can do is bring evidence of that complaint into the room. "I think my contrast vision has changed" is one kind of sentence. "I have these CSF readings over the past three months and the curve has dropped about 0.3 log units" is a different kind. The second is easier to look at together.
There's a small but real literature on this. Basch and colleagues' 2017 JAMA trial isn't about vision, but it captures the dynamic: cancer patients who self-reported symptoms longitudinally through a web tool had longer survival and fewer ER visits than usual-care controls — care teams caught drift earlier and acted on it sooner (Basch et al., 2017). The data wasn't doing the clinical reasoning; it was putting more on the table to reason about.
Before the appointment: what to prepare
Three things, in roughly this order. None of them is fancy.
At least two CSF readings, ideally three or more, with conditions noted. A single reading is a snapshot. Three or more across a few weeks is a trend you can point at. For each reading jot down the device, lighting, time of day, and how you were feeling — context that makes the data interpretable later. The longer treatment is in our self-tracking guide; for this visit, a couple of dated entries is enough.
The share-link URLs. The results page has a "Share my result" button that encodes the entire result — every frequency, the AULCSF, the date, the curve — into a URL. Save the link in your notes app. Three URLs is lighter than three screenshots, and your provider can pull the curve up in seconds.
A short symptom timeline. One paragraph: when did you first notice something different, what makes it better or worse, what specific tasks have changed (reading the menu in the dim restaurant, driving home at dusk, recognising colleagues across a meeting room). The CSF data says what the measurement is doing. The symptom timeline says what your life is doing. Both are needed.
One or two specific questions. Write them down. Not a dozen — your provider has fifteen useful minutes after the standard exam. Examples that travel well: "Given this curve, would you recommend an in-office contrast test?" or "Is this pattern something you'd want to follow up on, or watch?"
If you want a primer on what each piece of the test result actually means before you walk into the appointment, the explainer post reads quickly and will let you describe your own curve out loud.
The conversation: a script that works
The opening matters more than the content. Lead the wrong way and you've spent a third of your appointment getting back to neutral.
Don't open with a diagnosis. "I think I might have early glaucoma / cataract / MS / post-concussion vision change" puts your provider into the position of confirming or correcting a self-diagnosis, neither of which is a good use of the visit.
Open with the data and what you've noticed. A version that works:
"I've been tracking my contrast sensitivity at home over the past couple of months. The curve looks like this, and it's dropped a bit at the mid frequencies. In real life, driving at dusk has been harder for a while, and faces in dim restaurants feel flatter. I wanted to bring this in so we could look at it together."
That sentence names the measurement, shows the data, anchors the data to lived experience, and invites your provider to lead from there.
If they ask what the test is, one sentence: "It's a Pelli-Robson-style adaptive psychophysical test that runs in a browser. It calibrates the screen with a card-resize and a blind-spot distance check, uses a 2-down-1-up staircase across five spatial frequencies, and produces a CSF curve and an AULCSF summary." The for-clinicians page and the methodology page are the longer versions if needed.
Then stop talking. Let them ask questions. Let them look at the curve. Let them decide what's worth doing about it. The visit goes best when the data does what it's meant to do — start a conversation — and then steps out of the way.
What they may suggest
If the curve and the symptoms warrant a closer look, your provider has a small menu of reasonable next moves. None is alarming. Most are routine.
An in-office contrast sensitivity test. A formal Pelli-Robson chart, low-contrast Sloan letters, or CSV-1000. Five to ten minutes, standardised lighting, the same kind of measurement in a controlled environment. If your home curve sits at the edge of the normative band, this is a reasonable confirmatory step.
A more comprehensive workup. Depending on what they see, they might add a dilated fundus exam, an OCT scan, a visual fields test, or colour vision check. Not signs that something is wrong — standard tools for pinning down what part of the visual pathway is doing what.
A referral to a specialist. An ophthalmologist for in-depth retinal or optic-nerve evaluation; a neuro-ophthalmologist or neuro-optometrist if the symptoms point at a neurological component (the NORA directory lists members trained in this). A referral isn't bad news — it's your provider matching the question to the right expertise.
Watch and re-test in six to twelve months. Sometimes the most defensible action is observation, especially if the change is small and there's no obvious cause to chase. "Let's run this again at your next visit" is a real plan, not a brush-off.
Lifestyle and optical tweaks. Up-to-date prescription, anti-reflective coatings, task lighting, screen brightness. Many small things move CSF measurably. Easy fixes get tried first.
All of these are reasonable. Contrast sensitivity is a functional measurement, and a change in it is a prompt to look more closely — not, on its own, a verdict that something specific is wrong.
What they probably won't do
A short list, so the absence of these actions doesn't read as dismissal.
They probably won't treat the CSF number directly. Contrast sensitivity isn't a disease — it's a measurement of how your visual system handles a class of stimuli. A reduced curve signals that something is moving — possibly a refractive change, possibly early lens opacity, possibly a neurological signal, possibly fatigue, possibly the ambient light in your kitchen when you tested. The clinical response is to look for the cause, not "treat the curve."
They probably won't diagnose from a home test. Even a well-calibrated browser-based test isn't a clinical instrument under controlled conditions. The Pelli-Robson chart itself has test-retest repeatability of about ±0.15 log units and a clinically meaningful change threshold of about ±0.30 log units (Pelli, Robson & Wilkins, 1988); remote testing on consumer displays is noisier. A single result is a starting point.
They probably won't order expensive tests without a clinical indication. OCT, formal visual fields, MRI of the orbits — these get used when the rest of the exam, the symptoms, and the trajectory together justify them. Asking based on a home test alone tends to get a polite "let's see what the exam shows first," and that's the right answer.
None of this is a problem. It's clinical reasoning doing its job.
If the data doesn't land
Occasionally the conversation goes sideways. The provider waves the data off or says some version of "I wouldn't put much stock in an online test." Here's what helps and what doesn't.
Acknowledge the limit first. "I understand a home test isn't a clinical instrument, and the lighting and screen aren't controlled." This is true, and saying it out loud takes the wind out of any defensive reaction. You're not claiming the test replaces their exam.
Pivot to the lived experience. "The reason I brought it is that my real-world vision feels different — driving at dusk specifically. Can we look at contrast sensitivity in the exam itself today?" This shifts the request from "interpret my home data" to "run your own test." Most offices have at least low-contrast acuity options on hand.
If it still doesn't land, consider a different room. A neuro-optometrist is trained for the visual-functional complaint that doesn't reduce to a refraction. A second opinion within optometry, or a neuro-ophthalmology referral, is also fair — not because your provider is wrong, but because some questions belong with the specialist who sees them every day.
Don't escalate, don't argue. Your relationship with your eye-care provider is long-term. If the data didn't move the needle this time, take the test again in a month or two and bring the updated trend back. A line is harder to dismiss than a dot.
What this test can — and can't — replace
The honest map. The at-home test does not replace the dilated fundus exam, intraocular pressure measurement, refraction, the slit-lamp exam, OCT imaging, perimetry, or a properly-administered in-office Pelli-Robson chart. Those are clinical tools used by clinicians, and they catch things a browser test cannot.
What the at-home test does offer is a layer those snapshot exams don't: a longitudinal record collected on the same device, in the same room, over weeks or months. That continuity is its real contribution. The 1.84 / 1.68 log CS norms your optometrist might quote come from Mäntyjärvi and Laitinen — useful as a yardstick, but a single point on a single day (Mäntyjärvi & Laitinen, 2001). Your eight readings over three months are a different object. Use the home test for what it's good at, and leave the diagnostic question to the people in the exam room.
The smallest version of this you can do
If everything above feels like a lot, here's the compressed version. Take the test. Save the share link. Take it again next week, save that one too. Bring both links to your next eye exam. Open with: "I've been tracking my contrast sensitivity. I wanted to show you what I'm seeing." Stop talking. See what your provider says.
That's the whole exercise. The point is to walk in with one more useful piece of evidence than you'd otherwise have had, and put it on the table in a way that helps the conversation.
The graph is yours. The appointment is theirs. The conversation is what happens when both show up.
References
- Pelli, D. G., Robson, J. G., & Wilkins, A. J. (1988). The design of a new letter chart for measuring contrast sensitivity. Clinical Vision Sciences, 2, 187–199. The clinical Pelli-Robson chart and the load-bearing source for the test-retest repeatability (±0.15 log units) and clinically meaningful change threshold (±0.30 log units) that any at-home record needs to be read against.
- Mäntyjärvi, M., & Laitinen, T. (2001). Normal values for the Pelli-Robson contrast sensitivity test. Journal of Cataract and Refractive Surgery, 27(2), 261–266. The age-stratified normative log contrast sensitivity values overlaid on most modern reports — about 1.84 at age 20–39, drifting to about 1.68 at age 60 and above, binocular about 0.15 higher.
- Basch, E., Deal, A. M., Dueck, A. C., Scher, H. I., Kris, M. G., Hudis, C., & Schrag, D. (2017). Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA, 318(2), 197–198. Randomised trial in metastatic cancer in which patients self-reporting symptoms longitudinally through a web tool had longer overall survival and fewer emergency-department visits than usual-care controls — the modern citation for the value of patient-collected longitudinal data in clinical conversations.